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 Laboratory processing pathways have a significant impact on the overall 
management of patients with sepsis.  Retrieval and isolation of the suspected pathogen 
from a patient blood culture specimen is required for a definitive diagnosis of bacterial 
septicemia. Reference laboratories are high-volume facilities most often located some 
distance away from the collecting facility. Given the lengthy work up already required 
for blood culture pathogen analysis, reference laboratories must identify ways to 
optimize every step of the blood culture pathway in the effort to decrease turnaround 
time and mitigate lag time to final pathogen identification incurred by prolonged 
collection-to-incubation times.  Rapid molecular diagnostic methods independent of 
culture results is an available potential solution. The focus of this paper is to consider 
published literature on the evaluation of rapid blood culture testing to identify its 
potential benefits and ultimately layout a properly developed implementation plan that 
integrates the Verigene microarray-based rapid blood culture testing system 
(Nanosphere, Northbrook, IL, USA) into the blood culture workflow at a high-volume 
reference laboratory. 
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Introduction: The need for rapid blood culture testing 
Sepsis is defined as a life-threatening organ dysfunction caused by a 
dysregulated host response to infection. This definition of sepsis was recently revised in 
2015 to 1) reflect the overall understood syndromic pathobiology of the clinical 
condition and 2) to differentiate its need for urgent recognition in comparison to other 
types of infections (1).  It is reported that approximately 582,000 episodes of septic 
infections in North America are documented per year and at least 250,000 Americans 
die from sepsis each year, making sepsis the leading cause of death by infection in the 
United States (2,3).  
An increase in mortality rate is directly related to delays in reportable results for 
infections considered medical emergencies thus, in the case of sepsis, any delays prove 
significant when appropriate therapy is dependent on pathogen identification and 
susceptibility turnaround time (4,5). Retrieval and isolation of the suspected pathogen 
from a patient blood culture specimen is required for a definitive diagnosis of bacterial 
septicemia. This process can take between 1 and 3 days after a presumptive positive flag 
has been identified (5).   
Laboratory processing pathways have a significant impact on the overall 
management of patients with sepsis and delays to appropriate patient care can be 
observed anywhere from collection to reporting (8). Pre-analytical factors like whether a 
blood culture is processed in the same facility where bedside collection took place or 
processed at a core laboratory away from bedside collection location are important to 
consider when the concern for turnaround time is as urgent as is with blood culture 
testing. Core laboratories, also known as reference laboratories are high-volume 
facilities that process anywhere between 100,000 specimens a year to over 1,000,000 
specimens a year and are most often located some distance away from the collecting 
facility (6). Given the lengthy work up already required for blood culture pathogen 
analysis, reference laboratories must identify ways to optimize every step of the blood 
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culture pathway in the effort to decrease turnaround time and mitigate delay time to 
final pathogen identification incurred by prolonged collection-to-incubation times.   
While the need for rapid microbiology results was discussed in literature dating 
back to the 1980’s, rapid molecular testing platforms within microbiology laboratories 
have only begun to be a norm during the last decade (8).  Culture-based methods to 
identify pathogens remain the gold standard and prove necessary as comprehensive 
susceptibility information is required for appropriate therapy however, results obtained 
from rapid molecular testing platforms, independent of culture, have recently been 
acknowledged as necessary (9). The focus of this paper is to consider published 
literature on the evaluation of rapid blood culture testing to identify its potential 
benefits and ultimately layout a properly developed implementation plan that 
integrates the Verigene microarray-based rapid blood culture testing system 
(Nanosphere, Northbrook, IL, USA) into the blood culture workflow at a high-volume 
reference laboratory. Due to unforeseen proprietary issues the high-volume reference 
laboratory name and location will remain undisclosed.  
Benefits to implementing rapid blood culture testing  
Most documented benefits to adopting rapid blood culture testing are centered 
around the clinical aspect of patient care.  Separate studies performed by MacVane et 
al., and Perez et al., demonstrate a significant impact to effective therapy selection as 
well as a more rapid approach by providers to utilize narrow-spectrum antibiotics 
(11,12). This prompt de-escalation of antimicrobial therapy is relevant not only to 
hospitalized patient outcomes but also directly related to hospital costs. Documented 
analysis of patient hospital length of stay and total hospital cost between two controlled 
studies at one hospital, identified nearly $20,000 average reduction in cost when 
comparing pre- and post-rapid pathogen identification platform integration (12). It is 
important to note that the aforementioned studies demonstrate maximum benefits are 
obtained when appropriate action is taken by antimicrobial stewardship programs in 
place (11,12).   
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A more global benefit to implementing rapid blood culture testing is the 
additional role that clinical microbiology laboratories can play on decreasing the 
selective pressure for pathogen resistance. Rapid blood culture testing platforms 
provide pathogen identification and information about clinically relevant resistance 
markers with high accuracy when compared to conventional methods (10). Reducing 
the time required for identification and susceptibility reporting from 48 – 72 h to less 
than 24 h, after positive flag, may have a potential impact on lessening the spread of 
multidrug resistant bacterial strains through the de-escalation of antimicrobial therapy.  
The United States government, in line with Center for Disease Control guidelines, 
identifies the need for the use of rapid and innovative diagnostic tests for the 
identification and characterization of resistant bacteria (14). Delays associated with the 
normal turnaround time of conventional microbiology methods leads to extended 
periods of treatment with broad-spectrum empiric therapy and although considered the 
appropriate choice for treating early stages of septicemia, can add to the selective 
pressure for pathogen resistance (13).  Sautter et al. looked at the role that Labs have 
on lowering infection rates of multi-drug resistant infections and point out that 
laboratory administrators should consider the value in information that laboratory 
results provide on a larger scale when making decisions to support equipment that 
provide rapid diagnostic results (13). 
Time is of the essence when it comes to definitively diagnosing sepsis.  Blood 
culture bottles should be delivered to the processing laboratory soon after collection to 
avoid instrument incubation loading delays and ultimately time to pathogen detection 
delays (13). Pre-analytical delays incurred by processing blood cultures at a reference 
laboratory may inadvertently pose a risk to patient treatment by prolonging the time to 
detection of organisms.  Although manufacturers specify collected blood culture bottles 
may be held at 25°C for up to 24 h prior to loading into a continuous-monitoring blood 
culture instrument without compromising results, a controlled study suggests 
temperature and holding time before incubation can lead to an increase in time to 
positive detection as well as a decrease in organism detection as a whole (13).  Rapid 
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blood culture testing platforms offer clinically useful information on average 1.5-1.7 
days sooner than the results obtained by conventional methods (11,15). If pre-analytical 
factors like specimen transport cannot be modified then the opportunity for improving 
turnaround times through testing platforms that provide rapid diagnostic results should 
be strongly considered.   
Comparable assays: Verigene vs FilmArray   
The main focus of this paper is to develop an implementation plan to integrate 
the Verigene assay into the positive blood culture workflow of a high-volume reference 
laboratory.  Although a number of nucleic acid diagnostic assays are available for rapid 
pathogen detection directly from blood culture, the Verigene platform has been 
previously chosen by administrators and validated for use by research and development 
at the reference laboratory. Reasoning for choosing the Verigene platform over others 
on the market was not disclosed.  In an effort to make an informed conclusion about the 
Verigene assay a brief comparison to FilmArray (BioFire Diagnostics, Salt Lake City, UT), 
a similar rapid blood culture identification assay, will be made. Both Verigene and 
FilmArray are qualitative multiplexed testing platforms that use slightly different nucleic 
acid technologies to detect multiple pathogens and select genetic determinants directly 
from positive blood culture bottles (16-18).  
 The Verigene molecular assay detects nucleic acid targets of the pathogens 
listed in Table 1 via a microarray-based capture and mediator oligonucleotide system in 
the self-contained single use blood culture gram-positive test cartridges (BC-GP) and the 
single use blood culture gram-negative test cartridges (BC-GN).  Verigene technology 
(Processor SP and Verigene Reader) requires minimal hands on time for nucleic acid 
extraction; after blood culture gram stain evaluation, 350uL and 700uL of well mixed 
positive blood culture specimen is respectively added into the required BC-GP or BC-GN 
test cartridge aliquot well and programed into the Processor SP (VPSP).  In this closed 
system, bacterial DNA is extracted, denatured, fragmented and allowed to hybridize 
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with target specific oligonucleotides covalently bound to a glass microarray slide inside 
the Verigene Test Cartridge (VTC).  
Additional steps with mediator oligonucleotides, gold nanoparticle probes, and a silver 
enhancement step is required to efficiently detect presence of bacterial targets (Fig. 1). 
According to manufacturer specifications once hybridization is complete within the 
VPSP, the VTC can be loaded into the Verigene Reader within 12 hours for accurate 
detection. A 2- 2.5 h turnaround time from specimen loading to initial results is 
documented. Technology specifics were obtained from Verigene BC-GP and BC-GN FDA 
510(k) Summary submissions (17).   
FilmArray Blood Culture Identification Panel (BCID) detects all of its bacterial 
nucleic acid sequences (Table 1) simultaneously in one closed system known as the 
Blood Culture Identification Panel (BCID), through two stages of PCR and an end analysis 
TABLE 1 : IDENTIFICATION AND RESISTANCE TARGETS 
Figure 1.  Basic illustration outlining the steps of Verigene technology.  Capture and 
mediated oligonucleotide assay utilizing gold-nanoparticle probe and silver 
enhancement. 
FIGURE 1 : BASIC ILLUSTRATION OF VERIGENE TECHNOLOGY 
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of melt curves in replicate. The FilmArray platform has two main components 1) the 
Loading Station and 2) the FilmArray Instrument (FilmArray Torch). Minimal hands on 
time is also required to initiate nucleic acid extraction. After hydration fluid has been 
injected to properly reconstitute the freeze-dried enclosed reagents, 200ul of positive 
blood culture specimen mixed with sample buffer is added to the sample injection port 
of the FilmArray Pouch. The FilmArray pouch is described as an enclosed circuit that 
allows compartmentalized nucleic acid purification in which the first PCR reaction, the 
second PCR reaction and the end melting temperature analysis takes place. The first PCR 
reaction is a multiplexed PCR reaction performed to enrich the target nucleic acids in 
the sample while the second PCR reaction is diluted and mixed with a double stranded 
fluorescent binding dye to be performed in an array of individual wells, specifically for 
each target in triplicate, for every diagnostic target. The presence or absence of 
diagnostic targets are identified by DNA melt curve data collected and compared with 
internal control data. Technology specifics were obtained from FilmArray (BCID) Panel 
510(k) Decision Summary (18).  
Pathogen identification differences between the two assays are present and 
each platform has advantages over the other.  The FilmArray BCID for example, detects 
Haemophilus influenzae and Neisseria meningitidis both of which are not detected by 
the Verigene BC-GN assay.  Rapid diagnosis of both, H. influenzae and N. meningitidis, is 
deemed clinically significant since in both cases patients may worsen rapidly.  The 
Verigene BC-GP panel identifies three Staphylococcus species to genus level: 
Staphylococcus aureus, Staphylococcus epidermidis, and Staphylococcus lugdunensis 
whereas the FilmArray assay only identifies Staphylococcus aureus to species level. In 
2012, a review of sepsis incidence and sepsis pathogen recovery, implicated gram-
positive organisms as the most common organisms isolated from positive blood cultures 
and accounting for 52% to 77% of bacterial sepsis (19).  It is an advantage to rapidly 
identify coagulase negative staphylococcus species (CNS) like S.epidermidis and 
S.lugdunensis because of their more recently understood roles as pathogens (19,20). 
Verigene BC-GP and BC-GN combined offer the ability to detect 9 of the most common 
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resistance markers including some of the most concerning carbapenamase resistance 
genes (Table1).  Since the first Enterobacteriaciae carbapenemase resistant organism 
was identified in 1993 the concern to rapidly identify these multidrug resistant species 
has grown (21). The FilmArray BCID assay does not offer detection for extended 
spectrum beta-lacatam (ESBL) resistance genes, however, it does detect one other 
gram-negative pathogen to species level that the Verigene BC-GN does not, 
Acinetobacter baumanii.   This Acinetobacter sp. is recognized as a major drug-resistant 
organism implicated in nosocomial infections (16). 
Assay limitations exist for both platforms and a number of them have been 
compiled in Table 2. The following limitations described, although not all inclusive, 
appear to show significant variability in performance and should be considered by 
laboratory scientists upon final result review.   
TABLE 2: ASSAY LIMITATIONS 
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Both FilmArray and Verigene BC-GP/BC-GN demonstrate reduced sensitivity in 
accurately detecting organisms directly from polymicrobial blood cultures (18,10).  
When compared to other rapid identification platforms, literature documents that the 
BC-GP assay more successfully identifies at least one organism from polymicrobial blood 
cultures (21).  Misidentification of organisms is shared between FilmArray BCID and 
Verigene BC-GP/BC-GN; both platforms are unable to distinguish between Escherichiae 
coli and Shigella sp., the BC-GP misidentifies Streptococcus mitis/oralis as Streptococcus 
pneumoniae, BC-GN shows cross reactivity between Klebsiella oxytoca and Klebsiella 
pneumoniae, BCID may not be able to detect all Streptococcus sp. and also shows 
misidentification of Serratia marcesens as Pseudomonas aeuriginosa, Pseudomonas 
putida or Pantoea sp. (10,18,21). Procedural limitations for FilmArray BCID include the 
inability to use charcoal containing media for testing and the potential for pouch control 
failures due to resin beads contained in blood culture media (18). The latter a source of 
error requiring careful attention by the microbiologist upon initial set up.  A gram-stain 
is an essential part of positive blood culture work up procedures, nonetheless, it is 
considered a procedural limitation of the BC-GP and BC-GN assays when compared to 
FilmArray BCID.  A correct gram stain interpretation is required in order to choose the 
appropriate panel for identification on the Verigene platform (16,17). 
Implementing molecular diagnostics in a clinical microbiology lab is largely 
dictated by cost thus it is necessary to mention differences in cost between the two 
platforms.  A general list price inquiry comparison, reveals the unit price for Verigene to 
be more affordable than the newest FilmArray platform (FilmArray Torch).  CAP Today, 
product comparison webpage, documents a list price of $40,000 for the Processor SP 
and Verigene Reader required to run the Verigene BC-GP and BC-GN assays (22). It is 
important to note that one Verigene Reader is adapted to connect up to 32 Processor SP 
units; moreover, each Processor SP is capable of running one BC-GP or BC-GN at a time, 
each of which cost $20,000 per unit (22). The list price for the newest FDA approved 
(2016) FilmArray instrument, the FilmArray Torch, is $85,000 for the base model which 
includes 2 modules and the system analyzer.  Each module of the FilmArray Torch runs 
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one BCID pouch at a time and one analyzer can adapt up to 12 modules maximum. 
Additional FilmArray Torch modules are $10,000/2modules (Alex Sterling, Biofire 
Diagnostics, LLC, Sales Manager, personal communication).  To further compare cost, it 
is important to consider cost per test, however, a definitive value is dependent on a 
number of variables that can differ among facilities.  Blood culture positive volume at 
the evaluated high-volume reference laboratory could not be disclosed thus cost 
analysis was not included in this paper but the following values obtained from literature 
review can be used to approximate a difference in cost per test between assays: 
FilmArray BCID $129/per test, Verigene BC-GP/BC-GN $60-$99/per test (23-25).  An 
additional reference point for cost was obtained from a direct survey with a laboratory 
manager at a 200-bed nonprofit community hospital whose microbiology department 
uses the Verigene BC-GP and BC-GN for rapid blood culture detection.  When asked if 
BioFire FilmArray assay was considered upon integrating rapid blood culture testing, her 
response was “BioFire is too costly and reimbursement may be a problem for their 
panels.  Verigene is a reasonable in price.” Although reimbursement for testing should 
be considered, it may be more of an issue for a smaller hospital than it may be for a 
high-volume reference laboratory.  
Current blood culture positive workflow and suggested modifications    
 Besides minor changes like call notification documentation, the blood culture 
workflow procedure at the evaluated high-volume reference laboratory has remained 
the same for years. Moreover, new instrumentation with the potential to change 
workflow processes has not been introduced in over 15 years.  This section will aim to 
delineate the current blood culture positive workflow steps from the pre-analytical to 
the analytical as well as identify areas in need of improvement.    
 Before review of the current workflow was performed, a retrospective 
evaluation of laboratory information system (LIS) documented turnaround time was 
done for 108 nonduplicate specimens collected between December 2017 and February 
2018.  Average time from blood culture collection time to instrument load time, average 
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time to blood culture positive flag from documented load time, and the average time to 
organism identification from blood culture positive flag time, can be seen in Table 3.  All 
blood cultures are collected in SA Standard Aerobic, SN Standard Anaerobic, PF 
Pediatric FAN bottles and are incubated in the BacT/ALERT 3D (bioMérieux, Durham, 
NC, USA) continuous monitoring instrument.  
Steps in the pre-analytical phase cannot be addressed within the scope of this 
paper but it is important to acknowledge the average time of 8 hours that it takes for a 
blood culture to be loaded onto the incubation instrument from time of collection(Fig.2). 
The workup process for the current blood culture workflow follows the general principle 
of subculture, gram stain review, and gram stain result notification to appropriate 
provider.  Emphasis is placed on prompt incubation of subculture media at optimal 
conditions (37°C/CO2) to allow adequate bacterial growth for analysis early enough on 
day two of blood culture positive workflow (Fig. 2).  
The evaluated reference laboratory operates on a 24-hour 3 shift system with 
groups of employees starting at various times: Shift 1 includes groups starting every 
hour between 6 AM and 10 AM; groups in Shift 2 start every hour between 2 PM and 4 
PM (including a limited number starting at 3:30PM); and all employees on Shift 3 start at 
10 PM. Scheduling priority is given to the blood culture assignment to avoid gaps 
between shifts that may potentially lead to unnecessary delays in processing blood 
culture positives. Moreover, two skilled bacteriologists are scheduled per shift. All shift 
TABLE 3: AVERAGE TURN-AROUND TIME 
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members are to continuously perform tasks outlined in the analytical day 1 process (Fig. 
2) up to 6 hours of their assigned shift allowing the last two hours for post analytical 
documentation review of LIS documentation, slide archiving, and paper worksheet 
completion. The post-analytical steps are not included in Figure 2 nor Figure 4 as they 
do not affect the overall process of blood culture positive handling.   
 Although an advantage of using MALDI-TOF MS (Matrix assisted laser desorption 
ionization-time of flight mass spectrometry) for pathogen identification on day 2 of 
analysis exists, a review of the current blood culture workflow process highlights the 
prolonged amount of time it still takes for organism identification information to reach 
clinicians (Fig. 3). Summing the average amount of time it takes to update a report with 
a pathogen ID obtained on MS, with the average time from collection to initial positive 
blood culture flag, it is clear that efforts to decrease the time to identification still 
requires improvement in order to prove beneficial to the patient treatment outcome 
(Table 3).  
Figure 2. Current blood culture workflow.  Swim lane process map depicting steps in the three phases of the 
current blood culture workflow. Clock symbol indicates incubation time required. “Pulled” refers to positive blood 
culture bottle removed from continuous monitoring incubation instrument.  
FIGURE 2: CURRENT BLOOD CULTURE WORKFLOW 
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There are other areas, besides the need for rapid identification requiring 
acknowledgment that time and resources may not be efficiently utilized within the 
current workflow.  For example, literature states the importance of gram stain result 
notification, regarding it as a “critical value” carrying significant weight to correctly 
direct appropriate patient care, however, the current pathway places gram stain review 
second to subculture (26,27).  A high-volume reference laboratory may have over six 
incubation BacT/Alert 3D modules, each with 240 cells for monitoring, thus, the 
expected throughput of positives per 8-hour shift can be quite high on any given shift. 
Consideration to the amount of time it takes to organize, document, and subculture a 
large number of positives before gram stain review should be acknowledged as time 
directly affecting patient care. The logic behind inoculating solid agar media at the same 
time as slide preparation is to allow for subculture to be performed as soon as possible 
in order to maximize incubation time for better culture review on analytical day 2 
(Figure 2).  This however, is limited because review of blood cultures on analytical day 2 
requires supplemental media (i.e. additional selective solid agar media, tube coagulase 
to rule out Staphylococcus aureus, and disk diffusion screen plates) to be included. 
Furthermore, this additional media to be added is dependent on gram stain 
morphology.  Since supplemental media cannot be added until gram stain review is 
performed, incubation at the ideal 37°C/CO2 conditions is delayed. This process forces 
Figure 3. Timeline comparison, current workflow versus proposed workflow. Adjustment of therapy for 
gram-positive pathogens can be achieved >24 hours sooner by integrating BC-GP assay.  
FIGURE 3: TIMELINE COMPARISON 
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the bacteriologist in and out of the biohood as follows: 1) To organize biohood with 
necessary primary media (i.e. blood agar plates, chocolate agar plates, macconkey 
plates) 2) To label and inoculate solid agar media and gram stain slide 3) To add 
supplemental media to each respective blood culture and 4) To organize media for 
incubation after gram stain notification; consequently, allowing room for a decrease in 
overall work efficiency that may translate over to undesirable mistakes.  
 Standardization is an important step in optimizing any process and removing 
variability can lead to better efficiency. The current workflow allows employees to 
choose between two fixing methods before performing a gram stain: heat fix or 
methanol fix (Fig. 2).  Both fixing methods require blood samples inoculated on a glass 
slide to air dry completely before fixing for optimal results and use of crystal violet, 
iodine, decolorizer, and safranin immediately after fixing.  A simple study done to 
compare gram stain fixing methods, found methanol fixing to produce better looking 
stains over those that were heat fixed such that, a higher number of organisms adhered 
to slides and a decreased probability of gram-positives over-decolorizing were observed 
with methanol fixation (28). The former posing great risk to patient care resulting in 
missed organisms upon gram stain review and the latter commonly a source of error 
with organisms like Bacillus sp. and Clostridium sp. even amongst experienced 
bacteriologists (28). It appears counterintuitive to allow variability in a critical step of a 
workflow process. 
The last topic requiring discussion is that of inter-shift work endorsement. The 
current process requires a last “pull” of positives 2 hours before end of shift to allow for 
all work up and post-analytical review of LIS documentation to avoid carry over of 
unfinished processes to the next shift.  Flagged positive blood cultures during this last 2-
hours of this work up and documentation review time remain in the automated 
incubator for the next shift to process.  The attempt to minimize this “lag” time between 
shifts is done by scheduling an overlap between the last person that leaves a shift and 
the first person that arrives for a shift.  Since scheduling problems may arise from time 
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to time, it may be important to devise a set framework for continuous workflow to 
avoid turn-around delays for clinically significant results.  
Modified blood culture work-up method: Verigene implementation 
The initiative to integrate rapid blood culture testing was seriously considered at 
the evaluated high-volume reference laboratory back in 2015. For undisclosed reasons, 
the implementation was never followed up.  Per discussion with upper management 
overseeing research and development at the reference lab, interest in introducing the 
Verigene BC-GP assay into positive blood culture workflow processes exists and it is 
apparent that it will be more seriously considered upon laboratory expansion later this 
year.  It is the goal of this section to introduce a modified blood culture workflow that 
integrates rapid blood culture testing for gram positive organisms and considers 
solutions to the aforementioned opportunities for improvement.  
The modified workflow process, in contrast to the current method, puts 
emphasis on gram stain review and call notification over subculture to address the 
critical component of gram stain evaluation, as it relates to provider notification and 
initiation of rapid identification assay (Fig. 4).  Immediately after gram stain review, BC-
GP panels will be set up for all gram-positive cocci in cluster, gram-positive cocci in pairs 
and/or chains, and any gram-positive rods isolated from aerobic blood culture bottles 
not previously identified by rapid assay (Fig. 5). During the 2 h BC-GP assay turnaround 
time, gram stain notification is performed per shift protocol, media is respectively 
organized/labeled, subculture in biohood is performed, and subcultures are 
appropriately incubated at optimal 37°C/CO2 conditions (Fig. 4).  Since identification to 
species level will be obtained for the most common gram-positive blood culture 
pathogens (Table 1) on analytical day 1 (Fig. 4) the need for tube coagulase to rule out 
Staphylococcus aureus and disk diffusion screen plates specific for gram-positive 
pathogens is eliminated.  Additionally, when the bacteriologist is ready to go into the 
biohood for subculture, all necessary media will be labeled and ready for inoculation. 
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Upon incubation of first “pull” subcultures, the bacteriologist will ensure Blood 
Culture Positive Worksheet is filled in (Appendix A) and necessary LIS documentation 
has been verified before continuing on with the process.  Moreover, before gram stain 
reviews are performed on subsequent “pulls” or shortly thereafter, one of the two 
scheduled bacteriologists should monitor the Verigene instrument (assigned as an 
alternate workflow pathway and indicated as a dotted line on Figure 4) for pending BC-
Figure 4.  Proposed blood culture workflow. Swim lane process map depicting steps in the three phases of the proposed 
blood culture workflow. Clock symbol indicates incubation time required. “Pulled” refers to positive blood culture bottle 
removed from continuous monitoring incubation instrument. Diamond with encircled hexagon inside indicates decision 
activity dependent on fulfilled situation.  Dotted process flow line refers to alternate workflow pathway. 
FIGURE 4: PROPOSED WORKFLOW 
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GP results and document any completed results in LIS per information outlined in Figure 
6 and Table 4. 
The proposed process map includes two additional steps in analytical day 1, not 
present in the current process map, in an effort to address the need for continuous 
workflow and promote a structured endorsement of work between shifts. Additionally, 
changes to analytical day 2 were required to account for rapid identification performed. 
At the beginning of a shift, the scheduled bacteriologists must acknowledge receipt of 
any work from the previous shift and will assume responsibility to complete any 
additional tasks required as outlined on “End of shift protocol” (Figure 4).                 
Conversely, one hour before end of shift all flagged blood culture positives must be 
“pulled”, reviewed, documented on Inter-Shift Worksheet (Appendix B) and verified in 
LIS. Both additional steps detailing inter-shift work endorsement are assigned as an 
alternate workflow pathway and indicated as a dotted line on Figure 4. Rapid blood 
culture testing performed on analytical day 1 has an impact on workflow for analytical 
day 2. Figure 6 shows the decision algorithm required to evaluate BC-GP released 
results.  Any questionable results or non-phenotypic matches should be confirmed by 
MALDI-TOF MS.  
 
Figure 5.  Decision flow chart for Verigene blood culture gram-positive assay (BC-GP) set up.  
FIGURE 5: DECISION CHART FOR BC-GP SET UP 
17 
 
Anticipated workflow benefits and challenges 
Essentially, the BC-GP ID assay is not meant to take the place of any of the 
current steps of the workflow process thus as expected, when comparing process maps 
for the current and proposed method, the proposed method appears more 
cumbersome.  Benefits to workflow processes are not as obvious as one might presume 
but they do exist.   
TABLE 4: CALLS FOR VALID RESULTS 
FIGURE 6: DECISION CHART FOR RELEASING RESULTS 
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Although it is clear that additional steps are required to set up a supplementary 
method of identification on analytical day 1, hands on time for the Verigene BC-GP is 
less than 5 minutes (16,17). Moreover, the proposed workflow, outlines rapid ID to be 
limited to aerobic specimens without documented previous history hence anticipating a 
minor interruption of overall workflow (Fig. 5). These additional steps required in the 
analytical phase of day 1 will prove beneficial to the workflow in the analytical phase of 
day 2 in that, isolates with rapid ID results should require minimal phenotypic 
bacteriologist review before susceptibility workup can be initiated. A retrospective look 
at organism identification, for 108 randomly selected non-duplicate positive blood 
samples, demonstrated that over 80% of organisms identified by conventional method 
could have benefited from rapid identification on analytical day 1 (Table5). 
TABLE 5: MS ID FOR N=108 
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 When considering the total volume of blood culture positives that a high-volume 
reference laboratory may incur, this percentage can directly translate over to 
bacteriologist workup time which in turn translates over to laboratory cost.   
In further analyzing the workflow processes of the proposed plan one can 
identify other areas where bacteriologist time and efficiency can be improved. One area 
worth mentioning is the twofold benefit of focusing on gram stain review immediately 
after a blood culture positive is flagged; to the benefit of patient care, an immediate 
gram stain review can lead to faster turn-around times of clinically significant 
information reaching the clinician (Figure 3) and to the benefit of the bacteriologist, 
blood culture gram stain information available at the time of initial subculture allows for 
a streamlined process when gathering and organizing appropriate subculture media.  
 The task of including additional media based on gram stain review is made more 
efficient in the proposed method by eliminating the need for tube coagulase inoculation 
and plating of disk diffusion blood agar media.  This media is added to help screen for 
the most common gram-positive pathogens i.e. tube coagulase for Staphylococcus 
aureus, Bacitricin (A disk) for Streptococcus pyogenes, Optochin (P disk) for 
Streptococcus pneumoniae.  Identification to genus and species level by BC-GP assay will 
divert bacteriologist time from gathering, organizing, and sub-culturing additional media 
to setting up a rapid identification assay whose results, available in 2 hours, can be more 
clinically relevant than that of a documented tube coagulase result 18 - 24 h after 
positivity (Figure 3). The cost of eliminating tube coagulase and disk diffusion test set up 
may not be significant enough to offset the overall laboratory cost of implementing a 
rapid molecular identification test but when the clinical and economic impact is 
analyzed from the perspective of patient care the potential for cost savings can be 
significant.  
The proposed workflow is not without its challenges.  For example, the topic of 
continuous workflow, set forth, is not easy to address in large departments with high 
specimen volume. To avoid continuous workflow from being met with resistance by 
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staff members, the hand-off should be standardized.  The main goal of introducing an 
end of shift protocol is to set a framework with specific expectations that each shift 
must abide to in order for continuous workflow to be effective. Furthermore, in an 
effort to standardize the hand-off of pending work, documentation and accountability 
of performed tasks are required through the introduction of worksheets presented in 
Appendix B,C as well as in pre-integrated LIS scripted workup.  Any hand-off isolates 
requiring completion of additional tasks by the incoming shift should be clearly 
documented both on paper and in LIS. As previously mentioned, the evaluated 
reference laboratory gives scheduling priority to the blood culture positive task allowing 
for an overlap of bacteriologist between shifts however, scheduling conflicts are 
common and can lead to turn-around time delays.  A detailed look at the time between 
positive flag time and pulled time during shift changes may be necessary to prove the 
need for adopting a continuous workflow method.  A study performed in an effort to 
decrease the time to pathogen identification at a clinical microbiology lab in Houston 
Methodist Hospital, found that improving positive blood culture “pull” time can 
significantly decrease total processing time (27). Minor changes to the blood culture 
work up process at Houston Methodist Hospital lab improved the blood culture “pull” 
times from 38 m to 8 m (27).  It may be arguable that 30 minutes is not significant 
enough to impact patient care but, when mortality rate is increased by turn-around time 
delays and time for definitive pathogen identification is prolonged by the unavoidable 
pre-analytical aspect of processing a blood culture specimen at a reference laboratory, 
the impact can be regarded as more substantial.   
Limitations to the BC-GP assay causing discrepancies in reportable results must 
be addressed as additional challenges (Table 2). The proposed workflow process has 
integrated decision algorithms for both analytical day 1 and analytical day 2 that direct 
the bacteriologist to reject or confirm BC-GP assay results respectively depending on 
internal control results and phenotypic characteristics (Fig. 5, Fig. 3).  LIS reporting 
considerations must be taken to acknowledge the risk of false-positive results due to 
cross-reactivity between identifiable targets as well as due to its documented poor 
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performance in identifying organisms in polymicrobial cultures (17).  A report of, 
“Presumptive (insert organism and resistance marker if any) identification obtained by 
rapid ID method; culture results to follow.”, will be issued on the analytical day 1 of 
work up contingent on internal control results.  Including “Presumptive” in the initial 
preliminary report will allow for confirmation of results on analytical day 2. 
Furthermore, as detailed in Figure 5, if controls are “not detected” or a “no call” result is 
obtained, repeat testing will not be performed and a result of “Rapid ID unsuccessful; 
culture in progress.” will be reported.  
Conclusion and outlook 
  It is impossible to foresee all workflow challenges that may arise when 
implementing a new platform thus, the proposed workflow for the integration of the 
Verigene BC-GP assay into the established blood-culture work up method at the 
evaluated high-volume reference laboratory, is set forth as an initial framework to build 
upon.  Even if plans to integrate the Verigene assay are not fulfilled, there are a number 
of benefits to visually mapping out the current blood culture positive pathway as it has 
been done here.  Observations to specific potential problem areas were made in this 
process analysis and suggestions for improvement presented can be a topic for further 
discussion at department meetings.  
 My recommendation for the high-volume reference laboratory under evaluation 
is to try the proposed gram stain suggestions and presented continuous workflow steps 
before moving forward with integrating a rapid blood culture identification test. This 
may prove beneficial in the long run such that one test of change carried out in small 
scale can help anticipate potential problems and will allow staff to more easily adapt to 
upcoming changes.  A reasonable approach would be to direct one of two scheduled 
bacteriologists to adhere to the proposed continuous workflow process while the other 
follows established protocol to allow comparisons to be made side by side.   
The opportunity to integrate molecular diagnostics into microbiology testing, at 
the evaluated high-volume reference laboratory, comes with the need for expansion as 
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testing volumes continue to increase.   With this opportunity to integrate exciting new 
platforms also comes the opportunity to evaluate workflow processes with the end goal 
of optimizing a pathway that is known to have a big impact on patient care.  Clinical 
microbiology laboratories must not forget the role they play in the larger scheme of 
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